BMY
Bristol-Myers Squibb Co
ACTIONABLEMethodology gates passed
Position levels
Currenttoday
USD 64.72
Buy <=wait / entry
USD 54.00
Trim >=take some off
USD 66.00
Thesis breakDisclosure that Eliquis realised US net pricing has fallen materially beyond cur...
-
Scenario-weighted conviction
| Probability | Score | Contribution | |
|---|---|---|---|
| Bull case | 29% | 100 / 100 | 29.0 |
| Base case | 50% | 62 / 100 | 31.0 |
| Bear case | 21% | 10 / 100 | 2.1 |
| Weighted conviction | 62 / 100 - OPPORTUNISTIC BUY | ||
Top risks
- Strategic licensing deals with Hengrui Pharma covering 13 early-stage programs in oncology, hematology and immunology including co-development and commercialization options
- Upcoming Q2 2026 earnings report scheduled for July 30, 2026 with conference call at 8:15 a.m. ET
- Increased pricing pressure and restrictions from MCOs, PBMs and government-mandated cost-containment programs in the U.S. and abroad continuing to negatively affect revenues and profit margins